Responses by baseline BCR-ABL mutation
| . | 140 mg once daily, n = 158 . | 70 mg twice daily, n = 159 . | ||
|---|---|---|---|---|
| No. response/total . | % response . | No. response/total . | % response . | |
| MaHR | ||||
| No BCR-ABL mutation* | 51/75 | 68 | 56/81 | 69 |
| Any BCR-ABL mutation | 43/66 | 65 | 46/70 | 66 |
| Excluding T315I mutation | 41/55 | 75 | 44/61 | 72 |
| MCyR | ||||
| No BCR-ABL mutation* | 33/75 | 44 | 33/81 | 41 |
| Any BCR-ABL mutation | 18/66 | 27 | 29/70 | 41 |
| Excluding T315I mutation | 18/55 | 33 | 29/61 | 48 |
| . | 140 mg once daily, n = 158 . | 70 mg twice daily, n = 159 . | ||
|---|---|---|---|---|
| No. response/total . | % response . | No. response/total . | % response . | |
| MaHR | ||||
| No BCR-ABL mutation* | 51/75 | 68 | 56/81 | 69 |
| Any BCR-ABL mutation | 43/66 | 65 | 46/70 | 66 |
| Excluding T315I mutation | 41/55 | 75 | 44/61 | 72 |
| MCyR | ||||
| No BCR-ABL mutation* | 33/75 | 44 | 33/81 | 41 |
| Any BCR-ABL mutation | 18/66 | 27 | 29/70 | 41 |
| Excluding T315I mutation | 18/55 | 33 | 29/61 | 48 |
MaHR indicates major hematologic response; and MCyR, major cytogenetic response.
Includes patients with a known polymorphism only.